CTOs on the Move

Instrumentation Laboratories

www.instrumentationlaboratory.com

 
Instrumentation Laboratories is a Bedford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

ACT Services

ACT Services is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IQuum

IQuum is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mirixa

We are advocates, not just providers. Leading health plans and patients to better outcomes through a broad range of medication therapy management (MTM) programs. Empowering connections that matter. Mirixa is the leading provider of MTM and targeted, pharmacist-delivered services to health plans. An MTM pioneer, we`ve been building connections since 2006 - harnessing the knowledge and skills of pharmacists to engage more patients and deliver measureable results. We have the largest and most comprehensive pharmacy services network in North America. And we create leading edge programs that reach beyond Medicare Part D compliance, helping health plans of all types deliver a more focused patient experience and positive outcome, while potentially reducing total healthcare costs. Our goal is your goal: to ultimately empower every patient to live a fuller, healthier life.

Joyn Bio

Probiotics for Plants, We design microbes for more sustainable agriculture.

resTORbio

resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio`s lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions. Initially, resTORbio is focused on developing medicines that address conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio has initiated a Phase 2b trial for its lead product candidate, RTB101, evaluating its potential to reduce the incidence of respiratory tract infections (RTI) in elderly individuals at increased risk of RTI-related morbidity and mortality. resTORbio`s lead program is built upon two Phase 2a clinical studies demonstrating promising safety and efficacy results in almost 500 elderly individuals.